JLE

Hématologie

MENU

Dosage de l’activité du facteur IX chez les patients hémophiles B substitués Volume 26, numéro 1, Janvier-Février 2020

  • [1] Van den Bossche D., Peerlinck K., Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018;40:21-29. Suppl. 1
  • [2] Adcock D.M., Strandberg K., Shima M., Marlar R.A. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B. Int J Lab Hematol. 2018;40:621-629. 6
  • [3] Martinuzzo M., Barrera L., Rodriguez M., D’Adamo M.A., López M.S., Otaso J.C. Do PT and APTT sensitivities to factors’ deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients ? Int J Lab Hematol. 2015;37:853-860. 6
  • [4] Toulon P., Eloit Y., Smahi M., Sigaud C., Jambou D., Fischer F. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int J Lab Hematol. 2016;38:389-396. 4
  • [5] Kitchen S., Signer-Romero K., Key N.S. Current laboratory practices in the diagnosis and management of haemophilia : a global assessment. Haemophilia. 2015;21:550-557. 4
  • [6] Hubbard A.R., Dodt J., Lee T., Mertens K., Seitz R., Srivastava A. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013;11:988-989. 5
  • [7] Béné M.-C., Martinez P., Lasne D., Noizat-Pirenne F. Guide des analyses en hématologie. Société française d’hématologie. Paris: Elsevier Masson; 2018.
  • [8] Aznar J.A., Cabrera N., Matysiak M., Zawilska K., Gercheva L., Antonov A. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Haemophilia. 2009;15:1243-1248. 6
  • [9] Berntorp E., Björkman S., Carlsson M., Lethagen S., Nilsson I.M. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost. 1993;70:768-773. 5
  • [10] Bowyer A.E., Hillarp A., Ezban M., Persson P., Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits : a two-center study. J Thromb Haemost. 2016;14:1428-1435. 7
  • [11] Wilmot H.V., Hogwood J., Gray E. Recombinant factor IX : discrepancies between one-stage clotting and chromogenic assays. Haemophilia. 2014;20:891-897. 6
  • [12] Dodt J., Hubbard A.R., Wicks S.J., Gray E., Neugebauer B., Charton E. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing : challenges for caregivers and regulators. Haemophilia. 2015;21:543-549. 4
  • [13] Turecek P.L., Abbühl B., Tangada S.D., Chapman M., Gritsch H., Rottensteiner H. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Rev Clin Pharmacol. 2015;8:163-177. 2
  • [14] Kitchen S., Gray E., Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia. 2014;20:36-42. Suppl. 4
  • [15] Kershaw G.W., Dissanayake K., Chen V.M., Khoo T.-L. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia. 2018;24:492-501. 3
  • [16] Gritsch H., Romeder-Finger S., Scheiflinger F., Turecek P.L. Potency assignment and measurement of recombinant FIX activity in human plasma impact of reagents on the 1-stage clotting assay. Haemophilia. 201437. Suppl. 3
  • [17] Sommer J.M., Buyue Y., Bardan S., Peters R.T., Jiang H., Kamphaus G.D. Comparative field study : impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014;112:932-940. 5
  • [18] Dericquebourg A., Jourdy Y., Negrier C., Nougier C. Comparison of three assays for measuring factor IX. Haemophilia. 2018;24:51. Suppl.1
  • [19] Willemze A., Sadeghi-Khomami A., Sörskog L., Wikén M., Lethagen S. Assessment of clotting activity of recombinant fix FC fusion protein in European hemophilia treatment centers. Haemophilia. 2018;24:55. Suppl. 1
  • [20] Persson A., Mahmoud Hourani Soutari N., Norberg E.-M., Antovic J. One stage and chromogenic assays discrepancy in the estimation of factor IX (FIX) recovery. What is it that a single hemophilia center can and cannot do ? Replacement Therapy. 64th Annual meeting of the scientific standardization committee of the International society on thrombosis and haemostasis, July 18-21, 2018. Res Pract Thromb Haemost. 2019;17:138-148.
  • [21] Bowyer A., Sampson B., Shepherd F., Jones R., Kitchen S., Makris M. The FIX C assessment of extended half- life recombinant factor IX products in clinical practice. Haemophilia. 2018;24:56. Suppl. 1
  • [22] St Ledger K., Fuessner A., Kalina U., Metzner H.J., Horn C., Stowers A. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in the one-stage assay. Haemophilia. 2016;22:59. Suppl. 4
  • [23] Buyue Y., Rabinovich D., Bardan S., Hong V., Ismail A., Sommer J. Product-specific calibration standards do not correct one-stage clotting assay discrepancies for modified recombinant FIX molecules with reagents that significantly over- or under-recover labeled potency. Annual Meeting of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis. 2016;14:52. Suppl.1
  • [24] Florin L., Devreese K.M.J. Comparison of two one-stage clotting assays and one chromogenic FIX assay for monitoring of Idelvion replacement therapy. 64th Annual meeting of the scientific standardization committee of the International society on thrombosis and haemostasis. July 18-21, 2018. Res Pract Thromb Haemost. 2018;2:120. ®Suppl. 1
  • [25] Vangenechten M., Maes M., Maes M.B., Gadisseur A. Differences in activity of plasma spiked with IDELVION generated with one-stage clotting assay using different commercial APTT reagents compared with chromogenic method. 64th Annual meeting of the scientific standardization committee of the International society on thrombosis and haemostasis. July 18-21, 2018. Res Pract Thromb Haemost. 2019;17:138-48. ®
  • [26] Horn C., Négrier C., Kalina U., Seifert W., Friedman K.D. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2019;17:138-48.
  • [27] Rosén P., Rosén S., Ezban M., Persson E. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016;14:1420-1427. 7
  • [28] Young G., Ezban M., Clausen W.H.O., Negrier C., Oldenburg J., Shima M. Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol. Haemophilia. 2017;23:e528-e530. 6
  • [29] Tiefenbacher S., Bohra R., Amiral J., Bowyer A., Kitchen S., Lochu A. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost. 2017;15:1901-1912. 10
  • [30] Pouplard C., Trossaert M., Le Querrec A., Delahousse B., Giraudeau B., Gruel Y. Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia. 2009;15:365-368. 1